Sign in
My Cart
0
1. Global Market & Economic Outlook
The market is projected to maintain a steady growth trajectory. According to The Business Research Company, the global pharmaceutical intermediates market grew from $34.95 billion in 2025 to $37.38 billion in 2026, representing a compound annual growth rate (CAGR) of 7.0%. This growth is primarily attributed to the expansion of generic drug markets and the rising demand for high-purity intermediates for complex molecules.
Supply Chain & Tariffs: The market is facing "rapid changes in trade relations," particularly concerning tariffs. New tariffs are increasing the cost of imported raw chemicals, solvents, and catalysts. This is pressuring North American and European manufacturers while forcing Asia-Pacific exporters to adjust pricing strategies. However, this volatility is simultaneously accelerating investments in domestic intermediate manufacturing and regional supply diversification.
2. Regulatory Landscape: India’s Licensing Overhaul & EMA Guidelines
Regulatory oversight is tightening significantly in both emerging and mature markets.
India’s New Licensing Regime: In a major move to ensure drug safety and traceability, the Indian government is planning a separate wholesale licensing framework for bulk drugs, APIs, and Key Starting Materials (KSMs). Currently, raw materials and finished formulations operate under a common license. The proposed overhaul aims to create a registry of nearly 1.2 million bulk drug traders and improve oversight following global concerns over contaminated solvents. Given that over 70% of India’s bulk drug imports originate from China, this move also aligns with national security and supply chain resilience goals.
EMA Guideline Update: The European Medicines Agency (EMA) has released an updated Guideline on the chemistry of active substances, applicable from September 1, 2026. The revision places a "strong focus" on Nitrosamines and "cohort of concern" impurities. Intermediates manufacturers must now provide full process transparency, including quantitative data on reagents and quenching agents. The guidelines also enforce stricter rules on the recovery and reprocessing of materials, requiring a validated control strategy aligned with ICH Q11.
Domestic Chinese Regulations: As of January 2026, China has enforced a new "Drug Export Inspection and Certification Management Regulation," allowing intermediate products classified as "pharmaceutical preparation intermediates" to apply for export certificates. This ensures that intermediates manufactured under GMP conditions can access regulated international markets more easily.
3. Strategic Corporate & Manufacturing Expansions
India’s Capacity Push (Blue Jet Healthcare): Blue Jet Healthcare is breaking ground on a massive ₹2,300 crore (approx. $275 million) greenfield facility in Andhra Pradesh. Spanning 102 acres, the plant will focus on contrast media intermediates and high-intensity sweeteners. Notably, the facility will feature Zero Liquid Discharge (ZLD) technology, aiming for 70% energy reduction and 95% water recovery, aligning with global ESG standards. Operations are expected to begin by FY 2028-29.
PLI Scheme Momentum: The Department of Pharmaceuticals in India has reopened the application window for the Production Linked Incentive (PLI) scheme for critical intermediates, specifically for Meropenem and Ritonavir. This aims to boost domestic manufacturing of these antibiotic and antiviral intermediates, reducing import dependency.
Strong Earnings in CDMO & Intermediates:
Acutaas Chemicals (formerly Ami Organics) reported a stellar Q3 FY26, with revenue jumping 43% YoY to INR 393.2 crore. The company has revised its FY26 revenue guidance upward to 30%, driven by a healthy order book in pharmaceutical intermediates and CDMO services.
4. Technology & Sustainability Trends
The industry is shifting from generic bulk production to specialty and high-value intermediates.
-
Green Chemistry: There is a growing focus on continuous flow synthesis and green catalysis to reduce waste and energy consumption.
-
Digitalization: The European Pharmacopoeia (Ph. Eur.) transitioned to a fully digital format as of January 2026, streamlining access to quality standards for intermediates.
Summary Outlook
The pharmaceutical intermediates sector is currently in a "super-cycle" driven by the patent cliff for complex biologics and the surge in peptide-based drugs (GLP-1). While geopolitical friction and tariffs pose risks to supply chains, they are also catalyzing self-reliance in regions like India and the US. Companies that integrate forward into APIs and CDMO services, while adopting stringent environmental and impurity control measures, are best positioned for growth in 2026.
